■甲状腺毒症与心血管死亡率有关。这可能是由几种临床表现引起的,这些临床表现涉及三尖瓣反流(TR)和二尖瓣反流(MR)的罕见激发。然而,仍没有关于甲状腺毒性TR和/或MR的明确数据.这项研究检查了TR的进展,MR,对甲状腺毒性心脏表现的心力衰竭(HF)和肺动脉高压(PH),临床特点及治疗方法。
■使用PubMed和其他数据库进行了基于PRISMA的系统搜索,直到2023年6月17日。这项研究的结果是TR,MR,HF和PH随随访进展,临床特点及治疗方法。
■本研究共纳入57例病例报告,涉及62例患者(45.77±13.41年)。他们主要是女性(n=50;80.65%),被诊断患有Graves病(n=41;75.81%)。所有患者均诊断为甲状腺毒症,其中包括23例(37.10%)甲状腺风暴。从超声心动图研究来看,一些患者在随访的前6个月内临床上有所改善,包括20名TR患者(83.33%)在6个月,3个月内有9例MR患者(69.23%),2个月HF患者8例(66.67%),6个月PH患者16例(76.19%)。
■甲状腺毒性TR和/或MR涉及几种机制,包括甲状腺激素的直接作用和其他甲状腺功能亢进相关因素的间接作用。甲状腺毒性TR和/或MR患者,包括那些有HF和PH的,在头6个月的甲亢治疗后,可以经历临床和结构的改善。
UNASSIGNED: Thyrotoxicosis is related to cardiovascular mortality. This can be caused by several clinical manifestations involving the rare provocation of tricuspid regurgitation (TR) and mitral regurgitation (MR). However, there are still no clear data on thyrotoxic TR and/or MR. This study examines the progression of TR, MR, heart failure (HF) and pulmonary hypertension (PH) in response to the thyrotoxic heart manifestations, clinical characteristics and treatment approaches.
UNASSIGNED: A PRISMA-based systematic search was conducted using PubMed and other databases up to 17 June 2023. The outcomes of this study were TR, MR, HF and PH with their progression on follow-up, clinical characteristics and treatment approaches.
UNASSIGNED: A total of 57 case reports involving 62 patients (45.77 ± 13.41 years) were included in this study. They were predominantly women (n=50; 80.65%) and diagnosed with Graves\' disease (n=41; 75.81%). All patients were diagnosed with thyrotoxicosis, and this included 23 (37.10%) cases of thyroid storm. From echocardiographic studies, several patients improved clinically within the first 6 months of follow-up, including 20 TR patients (83.33%) in 6 months, nine MR patients (69.23%) in 3 months, eight HF patients (66.67%) in 2 months and 16 PH patients (76.19%) in 6 months.
UNASSIGNED: Several mechanisms are involved in thyrotoxic TR and/or MR, including the direct thyroid hormone effect and the indirect effect of other hyperthyroidism-associated factors. Patients with thyrotoxic TR and/or MR, including those with HF and PH, can experience clinical and structural improvements following hyperthyroidism treatment in the first 6 months.